生物制药公司Recursion Pharmaceuticals（RXRX）今日盘中大跌5.15%，主要原因是公司公布的第一季度财报未能达到分析师预期。
根据公司发布的财报，截至2025年3月31日的第一季度，Recursion Pharmaceuticals调整后每股亏损50美分，虽然略好于分析师平均预期的52美分亏损，但低于去年同期的39美分亏损。公司季度营收为1475万美元，同比增长6.9%，但未能达到分析师预期的1812万美元。此外，公司本季度净亏损高达2.0249亿美元，这些数据都引发了投资者的担忧。
值得注意的是，Recursion Pharmaceuticals今年以来股价已累计下跌29.7%。尽管如此，华尔街分析师对该公司的平均评级仍为"持有"，12个月目标价中位数为8.00美元。目前，有2个"强烈买入"或"买入"评级，6个"持有"评级，没有"卖出"或"强烈卖出"评级。这表明分析师对公司的长期发展仍持谨慎乐观态度，但短期内公司可能仍面临业绩压力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.